JP2024510666A5 - - Google Patents

Info

Publication number
JP2024510666A5
JP2024510666A5 JP2023557691A JP2023557691A JP2024510666A5 JP 2024510666 A5 JP2024510666 A5 JP 2024510666A5 JP 2023557691 A JP2023557691 A JP 2023557691A JP 2023557691 A JP2023557691 A JP 2023557691A JP 2024510666 A5 JP2024510666 A5 JP 2024510666A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
composition according
talazoparib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510666A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/052536 external-priority patent/WO2022200982A1/en
Publication of JP2024510666A publication Critical patent/JP2024510666A/ja
Publication of JP2024510666A5 publication Critical patent/JP2024510666A5/ja
Pending legal-status Critical Current

Links

JP2023557691A 2021-03-24 2022-03-21 Ddr遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ Pending JP2024510666A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163165723P 2021-03-24 2021-03-24
US63/165,723 2021-03-24
US202163282163P 2021-11-22 2021-11-22
US63/282,163 2021-11-22
US202263317368P 2022-03-07 2022-03-07
US63/317,368 2022-03-07
PCT/IB2022/052536 WO2022200982A1 (en) 2021-03-24 2022-03-21 Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer

Publications (2)

Publication Number Publication Date
JP2024510666A JP2024510666A (ja) 2024-03-08
JP2024510666A5 true JP2024510666A5 (cg-RX-API-DMAC7.html) 2025-03-31

Family

ID=80952181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557691A Pending JP2024510666A (ja) 2021-03-24 2022-03-21 Ddr遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ

Country Status (9)

Country Link
US (1) US20240180906A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313034A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024510666A (cg-RX-API-DMAC7.html)
KR (1) KR20230159510A (cg-RX-API-DMAC7.html)
AU (2) AU2022244439A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023018906A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214316A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011294A (cg-RX-API-DMAC7.html)
WO (1) WO2022200982A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202600137A (zh) 2024-04-04 2026-01-01 美商輝瑞股份有限公司 於使用parp抑制劑的治療作為預測性生物標記之tmprss2-erg和rbi及使用parp抑制劑之治療方法
WO2026078615A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2026078619A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
BRPI0709771B1 (pt) 2006-03-27 2022-01-25 The Regents Of The University Of California Composto e composição farmacêutica
NZ596260A (en) 2006-03-29 2013-05-31 Univ California Diarylthiohydantoin compounds
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
HUE035295T2 (en) 2008-08-06 2018-05-02 Medivation Technologies Inc Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
JP2012518661A (ja) 2009-02-24 2012-08-16 メディベイション プロステイト セラピューティクス, インコーポレイテッド 特定のジアリールヒダントインおよびジアリールチオヒダントイン化合物
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
WO2011044327A1 (en) 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
CA2787844C (en) 2010-02-03 2019-08-27 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
MX340319B (es) 2010-02-08 2016-07-06 Medivation Technologies Inc Procesos para sintetizar derivados de dihidropiridoftalazinona.
CN103282365B (zh) 2010-10-21 2017-12-29 麦迪韦逊科技有限公司 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐
EP3066084A1 (en) 2013-11-07 2016-09-14 Medivation Technologies, Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
EA201790290A1 (ru) 2014-07-31 2017-07-31 Медивэйшн Текнолоджиз, Инк. Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения
CN108883115A (zh) 2015-10-26 2018-11-23 麦迪韦逊科技有限责任公司 用parp抑制剂治疗小细胞肺癌
EA201992430A1 (ru) * 2017-04-13 2020-02-28 Янссен Фармацевтика Нв Комбинированная терапия рака предстательной железы
AU2018347331A1 (en) * 2017-10-13 2020-04-09 Merck Patent Gmbh Combination of a PARP inhibitor and a PD-1 axis binding antagonist
US20210355223A1 (en) * 2018-11-05 2021-11-18 Pfizer Inc. Combinations for Treating Cancer

Similar Documents

Publication Publication Date Title
US20230103007A1 (en) Combination therapy for treating abnormal cell growth
US20230321097A1 (en) Methods and compositions for treating abnormal cell growth
CN103945849B (zh) 癌症的联合治疗
US20230201198A1 (en) Methods of treating abnormal cell growth
JP2022510410A5 (cg-RX-API-DMAC7.html)
JP2002535249A (ja) 腫瘍を治療する放射線療法及びcox−2阻害剤の組合せ療法。
AU2018380174A1 (en) Use of PARP inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
WO2017118401A1 (zh) 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒
WO2019094053A1 (en) Disulfiram and copper salt dosing regimen
IL319922A (en) Combination of TALAZOPARIB and ENZALUTAMIDE in the treatment of metastatic castration-resistant prostate cancer
JP2024502446A5 (cg-RX-API-DMAC7.html)
CN120659606A (zh) 治疗转移性去势抵抗性前列腺癌的他拉唑帕尼及恩杂鲁胺的组合
JP2022543679A5 (cg-RX-API-DMAC7.html)
US11000518B2 (en) Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer
WO2007108272A1 (ja) 癌治療用キットおよび癌治療用医薬組成物
Arnott The value of combined 5-fluorouracil and x-ray therapy in the palliation of locally recurrent and inoperable rectal carcinoma
JP2025511402A5 (cg-RX-API-DMAC7.html)
Hahn et al. Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer
WO2020057536A1 (zh) 用于治疗脑肿瘤的喹啉衍生物
CN104968340A (zh) 治疗肝脏疾病或病状的用途和方法
CN116322690A (zh) 组合的药物抗癌疗法
US20260041676A1 (en) Combination Therapy
CN110613713B (zh) 3-羟基氨基苯甲酸与索拉非尼联合用药治疗肿瘤
TW202448458A (zh) 雌激素受體降解劑與akt抑制劑之組合
WO2019174590A1 (zh) 用于治疗三阴性乳腺癌的喹啉衍生物